中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (3): 587-593.doi: 10.4103/1673-5374.347740

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

轻度认知功能障碍早期诊断的生物标志物:fibulin-1

  

  • 出版日期:2023-03-15 发布日期:2022-08-27
  • 基金资助:

    国家自然科学基金青年基金(81801071);重庆医科大学研究生拔尖人才培养项目 (BJRC202106)

Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment

Bo Chen1, #, Li Song2, #, Juan Yang3, Wei-Ying Zhou1, Yuan-Yuan Cheng3, Yu-Jie Lai3, *   

  1. 1College of Pharmacy, Chongqing Medical University, Chongqing, China; 2Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Major Neurological and Mental Disorders, Chongqing Key Laboratory of Neurology, Chongqing, China; 3Department of Neurology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • Online:2023-03-15 Published:2022-08-27
  • Contact: Yu-Jie Lai, PhD, laiyujie0206@163.com.
  • Supported by:
    This study was supported by the National Natural Science Foundation of China, No. 81801071 (to YJL) and Top-notch Postgraduate Talent Cultivation Program of Chongqing Medical University, No. BJRC202106 (to BC).

摘要:

轻度认知功能障碍是阿尔茨海默病病理的前驱症状。由于缺乏早期症状和局限于传统的诊断方法,认知功能障碍患者往往被延迟诊断。外泌体在细胞与细胞的交流中发挥着重要作用,可以作为诊断疾病的有前途的生物标志物。该研究旨在确定血清外泌体候选蛋白在诊断轻度认知功能障碍中可能发挥的作用。研究通过对比轻度认知功能障碍患者和健康对照人群中血清外泌体水平发现,与健康对照组相比,在轻度认知功能障碍 患者中血清外泌体浓度较高且直径较小。接着比较轻度认知功能障碍患者和健康对照人群的血清外泌体差异蛋白,发现轻度认知功能障碍患者的fibulin-1表达增高,且较高水平的外泌体fibulin-1与轻度认知功能障碍患者较低的认知能力相关。这些表明血清外泌体fibulin-1可能是诊断轻度认知功能障碍的生物标志物。

http://orcid.org/0000-0002-6006-1791 (Yu-Jie Lai)

Abstract: Mild cognitive impairment (MCI) is a prodrome of Alzheimer’s disease pathology. Cognitive impairment patients often have a delayed diagnosis because there are no early symptoms or conventional diagnostic methods. Exosomes play a vital role in cell-to-cell communications and can act as promising biomarkers in diagnosing diseases. This study was designed to identify serum exosomal candidate proteins that may play roles in diagnosing MCI. Mass spectrometry coupled with tandem mass tag approach-based non-targeted proteomics was used to show the differentially expressed proteins in exosomes between MCI patients and healthy controls, and these differential proteins were validated using immunoblot and enzyme-linked immunosorbent assays. Correlation of cognitive performance with the serum exosomal protein level was determined. Nanoparticle tracking analysis suggested that there was a higher serum exosome concentration and smaller exosome diameter in individuals with MCI compared with healthy controls. We identified 69 exosomal proteins that were differentially expressed between MCI patients and healthy controls using mass spectrometry analysis. Thirty-nine exosomal proteins were upregulated in MCI patients compared with those in control patients. Exosomal fibulin-1, with an area under the curve value of 0.81, may be a biomarker for an MCI diagnosis. The exosomal protein signature from MCI patients reflected the cell adhesion molecule category. In particular, higher exosomal fibulin-1 levels correlated with lower cognitive performance. Thus, this study revealed that exosomal fibulin-1 is a promising biomarker for diagnosing MCI.

Key words: Alzheimer’s disease, biomarker, diagnosis, exosomes, fibulin, mass spectrometry, mild cognitive impairment, tandem mass tag, cell adhesion molecule, nanoparticle tracking analysis